Abstract
Busulfan is widely used as a chemotherapy treatment before hematopoietic stem-cell transplantation (HSCT). However, the response of busulfan is highly variable and unpredictable, whereby the pharmacogenetic interference of glutathione S-transferase (GST) has strong evidence in Caucasians and some adult Asians but not in pediatric Asian patients. This study was aimed at investigating the associations of GST genetic polymorphisms with variations in the pharmacokinetic (PK) properties of busulfan in pediatric Asian patients. This retrospective cohort study recruited 92 pediatric patients. The polymorphism of GSTA1 was genotyped by Sanger sequencing, and GSTM1 and GSTP1 were genotyped by real-time PCR. Drug concentration and PK estimation were identified using an LC-MS/MS method and a noncompartmental model. Statistical analysis was performed by R software. Out of 92 patients, 48 (53%) were males, the mean age was 8.4 ± 5.12 years old, and the average weight was 26.52 ± 14.75 kg. The allele frequencies of GSTA1*B and of GSTM1 and GSTP1* deletions were 16.9%, 68.5%, and 21.2%, respectively. Patients with GSTA1*B had a statistically significant impact on the PK of busulfan, whereas those with GSTM1 and GSTP1 did not (p > 0.05). The carriers of GSTA1*B showed a significant difference compared to noncarriers in terms of t1/2 (for first dose: 161.9 vs. 134.3 min, p = 0.0016; for second dose: 156.1 vs. 129.8, p = 0.012), CL (88.74 vs. 124.23 mL/min, p = 0.0089), Cmax (4232.6 vs. 3675.5 ng/mL, p = 0.0021), and AUC (5310.6 vs. 4177.1 µM/min, p = 0.00033). The augmentation of AUC was around 27.1% in patients carrying the GSTA1*B variant. The GSTA1 polymorphism was significantly associated with variations of the pharmacokinetic properties of busulfan treatment in pediatric Asian patients.
Highlights
Busulfan is a bifunctional alkylating agent, widely used as chemotherapy treatment before hematopoietic stem-cell transplantation (HSCT)
In consideration of the abovementioned drawbacks, this study was aimed at investigating the potential impact of GSTA1, GSTM1 and GSTP1 genetic polymorphisms on the PK properties of busulfan in pediatric Asian patients
The genetic impacts of this specific population remained unknown until today because (1) children’s metabolism varies widely across individuals, and (2) there is a lower allele frequency in Asians than in Caucasians [10], with the exception of Israelis
Summary
Busulfan is a bifunctional alkylating agent, widely used as chemotherapy treatment before hematopoietic stem-cell transplantation (HSCT). High exposure of busulfan is needed to destroy cancer cells, but it can destroy normal hematopoietic cells. HSCT is used to “rescue” the patients from the side effects of chemotherapy [1]. Busulfan serves as a cornerstone for the success of this process, and as a replacement for total body irradiation (TBI) of the conditioning regimen before HSCT [2,3,4]. Exceeding the therapeutic range can cause graft-versus-host disease (GvHD), sinusoidal obstruction syndrome (SOS), and lower overall survival [5,6]. Going below the therapeutic range can cause graft failure and disease relapse [7]. Many attempts have been made to take into account the potential influencing factors, such as gender, age, weight, metabolism pathway and genetic profile
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
